Relapsing forms of multiple sclerosis (RMS) with active disease

Active Ingredient: Ofatumumab

Indication for Ofatumumab

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Ofatumumab is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

For this indication, competent medicine agencies globally authorize below treatments:

20 mg once a week at weeks 0, 1 and 2, followed by 20 mg once a month starting at week 4

For:

Dosage regimens

Subcutaneous, 20 milligrams ofatumumab, one dose, over the duration of 1 week. Afterwards, subcutaneous, 20 milligrams ofatumumab, one dose, over the duration of 1 week. Afterwards, subcutaneous, 20 milligrams ofatumumab, one dose, over the duration of 2 weeks. Afterwards, subcutaneous, 20 milligrams ofatumumab, once monthly.

Detailed description

The recommended dose is 20 mg ofatumumab administered by subcutaneous injection with:

  • initial dosing at weeks 0, 1 and 2, followed by
  • subsequent monthly dosing, starting at week 4.

Missed doses

If an injection is missed, it should be administered as soon as possible without waiting until the next scheduled dose. Subsequent doses should be administered at the recommended intervals.

Adults over 55 years old

No studies have been performed in MS patients over 55 years old. Based on the limited data available, no dose adjustment is considered necessary in patients over 55 years old.

Dosage considerations

The usual sites for subcutaneous injections are the abdomen, the thigh and the upper outer arm.

The first injection should be performed under the guidance of a healthcare professional.

Active ingredient

Ofatumumab

Ofatumumab is a fully human anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody. The binding of ofatumumab to CD20 induces lysis of CD20+ B cells primarily through complement-dependent cytotoxicity (CDC) and, to a lesser extent, through antibody-dependent cell-mediated cytotoxicity (ADCC).

Read more about Ofatumumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.